South Africa Osteoporosis Drugs Market Size & Outlook
The osteoporosis drugs market in South Africa is expected to reach a projected revenue of US$ 80.9 million by 2030. A compound annual growth rate of 4.7% is expected of South Africa osteoporosis drugs market from 2025 to 2030.
Revenue, 2024 (US$M)
$60.8
Forecast, 2030 (US$M)
$80.9
CAGR, 2025 - 2030
4.7%
Report Coverage
South Africa
Related Markets
South Africa osteoporosis drugs market highlights
- The South Africa osteoporosis drugs market generated a revenue of USD 60.8 million in 2024 and is expected to reach USD 80.9 million by 2030.
- The South Africa market is expected to grow at a CAGR of 4.9% from 2025 to 2030.
- In terms of segment, branded was the largest revenue generating product in 2024.
- Generics is the most lucrative product segment registering the fastest growth during the forecast period.
Osteoporosis drugs market data book summary
| Market revenue in 2024 | USD 60.8 million |
| Market revenue in 2030 | USD 80.9 million |
| Growth rate | 4.9% (CAGR from 2025 to 2030) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | Amgen Inc, Eli Lilly and Co, Merck & Co Inc, Novartis AG ADR, Pfizer Inc, GlaxoSmithKline, Radius Health, UCB SA, Teva Pharmaceutical Industries Ltd, Roche Holding AG |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.4% of the global osteoporosis drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia osteoporosis drugs market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 80.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Osteoporosis Drugs Market Scope
Osteoporosis drugs market segmentation & scope
Other
Osteoporosis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Radius Health | View profile | 251-500 | Cambridge, Massachusetts, United States, North America | http://www.radiuspharm.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
South Africa osteoporosis drugs market size, by product, 2018-2030 (US$M)
South Africa Osteoporosis Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
